Skip to content

XORTX
  • About
    • Management Team
    • Board of Directors
    • Advisory Board
  • Pipeline
    • Coronavirus – COVID-19 Program
    • Autosomal Dominant Polycystic Kidney Disease
    • Diabetic Nephropathy
  • Strategic Partnerships
  • Investors
    • Press Releases
    • Presentations
    • Media
    • Independent Research
    • Financials
    • SEDAR
    • Transfer Agent
    • Upcoming Events
  • Contact
Site Search

XORTX Therapeutics Provides Corporate Update

  • February 27, 2018December 22, 2020
  • by aaronbb

CALGARY, AB – February 27, 2018 – XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE:XRX), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to provide this corporate update.

“With the successful close of the Company’s recent merger with APAC Resources Inc. and the fund raise
associated with that transaction, XORTX is continuing its efforts to strengthen the XORTX team and has
made good advancements on the preparation of documents for review by the FDA for upcoming phase II
trials as well as identifying additional strategic programs to drive revenue and bolster value of XORTX,” stated Dr. Allen Davidoff, CEO.

XORTX Operations – These past couple of months has seen significant progress in the preparation of documents for review by the FDA for the Company’s upcoming phase II trials associated with XORTX’s lead programs to develop treatments for progressive kidney disease due to diabetes, diabetic nephropathy and polycystic kidney disease. XORTX continues to be encouraged by the number of studies and work being reported that validate the Company’s focus, patent portfolio and the importance of addressing this unmet medical need in progressive kidney disease. Notable recent publications on the need for XORTX’s drug advancement include:

https://www.renalandurologynews.com/hyperuricemia/chronic-kidney-diseasehyperuricemia-trajectories-esrd-mortality-tied/article/742944/

and,

http://www.renalandurologynews.com/hyperuricemia/ckd-hyperuricemia-uric-acid-lowering-treatment-helpskidney-disease-cv-events/article/707042/.

XORTX Team – XORTX continues to build its team with key corporate appointments including two new board members and a new Chief Financial Officer. New board members Paul Van Damme, who has a strong biopharmaceutical and finance background to head up the Company’s audit committee and Allan Williams, an independent businessman with strong ties to the financial community to assist XORTX with its capital raising needs going forward join XORTX founder Dr. Allen Davidoff and long time director Bruce Rowlands on the Company’s board of directors. XORTX has also strengthened its management team with David Matthews being appointed Chief Financial Officer. See press releases of January 29th and February 22nd.

About XORTX Therapeutics Inc.

XORTX Therapeutics Inc. is a BioPharmaceutical company focused on developing innovative therapies to
treat progressive kidney disease. XORTX has lead programs to develop treatments for progressive kidney
disease due to diabetes, diabetic nephropathy and polycystic kidney disease. Secondary programs focus
on developing therapies for health consequences that accompany pre-diabetes, diabetes and cardiovascular disease. Additional information on XORTX Therapeutics is available at www.XORTX.com.

For further information, please contact:
Erik Matthews, Corporate Communications & Investor Relations
+1-747-203-5240 or erik@xortx.com / ray@xortx.com

The CSE has neither approved nor disapproved the contents of this news release. No stock exchange,
securities commission or other regulatory authority has approved or disapproved the information contained herein.

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to share on Google+ (Opens in new window)

Related

XORTX Therapeutics Appoints Mr. Dave Matthews CFO
XORTX Announces Issuance of Stock Options

Press Releases

  • XORTX Confirms $1 Million in Warrant Exercise Proceeds March 2, 2021
  • XORTX Confirms $1 Million in Warrant Exercise Proceeds March 2, 2021
  • XORTX Participating in WuXI Healthcare Forum March 1, 2021
  • XORTX to Present at BIO CEO and Investor Conference February 17, 2021
  • XORTX Closes Over Subscribed Private Placement February 10, 2021

Archives

  • 2012 Press Releases 3
  • 2014 Press Releases 2
  • 2015 Press Releases 1
  • 2017 Press Releases 2
XORTX Therapeutics Inc.
4000, 421 7th Avenue SW
Calgary, Alberta T2P 4K9
Ph: +1 (403) 455-7727
info@xortx.com
Theme by Colorlib Powered by WordPress